CDKN2A and neoplasm: Another study, searching to validate tumor drivers and therapeutic targets, found CDKN2A to be mutated in 45% of 40 primary cSCC (20 well-differentiated and 20 moderately/poorly differentiated tumors), from both immunosuppressed and immunocompetent patients, by employing whole-exome analyses [31].